3 results
Scar volume and POSAS score will be measured in the Verapamil group, these will be compared to the scar volume and POSAS score in the Kenacort+Verapamil group and the Kenacort group. In addition, complications/ adverse effects will be reported.
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
The objective of this study is to investigate the added effect of an intramuscular (IM) gluteal corticosteroid injection above a placebo IM gluteal injection (saline) on pain symptoms in patients with hip OA, not responding satisfactory to the usual…